SEARCH

SEARCH BY CITATION

References

  • 1
    Medical Audit. A First Report –‘What, Why and How?’ London: RCP Publications, 1993.
  • 2
    Lee R, Monteiro EF. Third regional audit of antiretroviral prescribing in HIV patients. Int J STD AIDS 2003; 14: 5860.
  • 3
    Gazzard B, on behalf of the BHIVA Writing Committee. BHIVA Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005; 6 (suppl. 2): 161.
  • 4
    Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725733.
  • 5
    Smith CJ, Sabin CA, Youle MS et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190: 18601868.
  • 6
    DeHovitz JA, Kovacs A, Feldman JG et al. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: a report from the Women's Interagency HIV Study. J Infect Dis 2000; 182: 15271530.
  • 7
    May M, Sterne JA, Sabin CA et al. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21: 11851197.
  • 8
    Lampe FC, Smith CJ, Madge S et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Int Med 2007; 167: 692700.
  • 9
    May MT, Sterne JA, Costagliola D et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368: 451458.
  • 10
    Curtis H, Sabin CA, Johnson MA, on behalf of the British HIV Association Clinical Audit Committee. Findings of the first national clinical audit of treatment for people with HIV. HIV Med 2003; 4: 1117.
  • 11
    Brook MG, Curtis H, Johnson MA, on behalf of the British HIV Association Clinical Audit Committee. Findings from the British HIV Association's national audit of first-line antiretroviral therapy and survey of treatment practice and maternity care 2002. HIV Med 2004; 5: 415420.
  • 12
    Copeland G. A Practical Handbook For Clinical Audit. NHS Clinical Governance Support Team. London: Department of Health publications, 2005.
  • 13
    Stohr W, Dunn DT, Porter K et al. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997–2003. HIV Med 2007; 8: 135141.
  • 14
    Health Protection Agency. Testing Times – HIV and Other Sexually Transmitted Infections in the United Kingdom: 2007. London: Health Protection Agency, 2007, Available at http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1203496897276
  • 15
    Gazzard BG, on behalf of the BHIVA Treatment Guidelines Working Group. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy, 2008. HIV Med 2008; 9: 563608.
  • 16
    Health Protection Agency. HIV drug resistance in the United Kingdom: data to end of 2004. CDR Wkly 2006; 16.
  • 17
    UK Collaborative Group on HIV Drug Resistance. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21: 10351039.
  • 18
    Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 count and viral load. JAMA 2001; 286: 25602567.
  • 19
    Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119129.
  • 20
    Landon BE, Wilson IB, McInnes K et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch Intern Med 2005; 165: 11331139.
  • 21
    British HIV Association in partnership with the Royal College of Physicians, London, British Association for Sexual Health and HIV, British Infection Society. Standards for HIV Clinical Care. London: BHIVA, 2007.
  • 22
    Smith CJ, Staszewski S, Sabin CA et al. Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr 2004; 37: 11551159.
  • 23
    Cozzi Lepri A, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load. AIDS 2001; 15: 4754.